Runben Biotechnology Co (SHSE:603193) Stock Based Compensation: ¥0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603193 Runben Biotechnology Co Ltd SHSE:603193
70 GF Score
Price ¥20.54
GF Value ¥28.60
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Runben Biotechnology Co Stock Based Compensation?

Runben Biotechnology Co SHSE:603193 -1.25% 70 Stock Based Compensation is ¥0 Mil as of Jun. 2026. GuruFocus rates SHSE:603193 with a GF Score™ of 70/100 and a GF Value™ of ¥28.60 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Runben Biotechnology Co's Stock Based Compensation for the three months ended in Jun. 2026 was ¥0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ¥0 Mil.

Runben Biotechnology Co Stock Based Compensation Related Terms

Runben Biotechnology Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Runben Biotechnology Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Runben Biotechnology Co Stock Based Compensation Chart

Runben Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Runben Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:603193
70GF Score
Runben Biotechnology Co Ltd SHSE:603193
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Runben Biotechnology Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

What does a Stock Based Compensation of ¥0 Mil mean?
Runben Biotechnology Co (SHSE:603193) has a Stock Based Compensation of ¥0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Runben Biotechnology Co and its competitors.
Is Runben Biotechnology Co's Stock Based Compensation too high?
Runben Biotechnology Co's current Stock Based Compensation is ¥0 Mil. Overall, Runben Biotechnology Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's Stock Based Compensation compare to PG and CL?
Runben Biotechnology Co's Stock Based Compensation of ¥0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Consumer Packaged Goods company?
A good Stock Based Compensation depends on the Consumer Packaged Goods industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Runben Biotechnology Co and its competitors. Runben Biotechnology Co's current Stock Based Compensation is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.60, compared to a current price of ¥20.54 — trading 28.2% below its estimated fair value. The current Stock Based Compensation is ¥0 Mil. Runben Biotechnology Co's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current Stock Based Compensation is ¥0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?

Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued. The current stock price of ¥20.54 is trading 28.2% below its estimated GF Value™ of ¥28.60. GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.

Key valuation signals for SHSE:603193:

  • Stock Based Compensation: ¥0 Mil
  • GF Value™: ¥28.60 vs. price of ¥20.54 (28.2% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Runben Biotechnology Co Business Description

Address No. 3, Xinzhuang 5th Road, Guangzhou Economic and Technological Development Zone, Guangdong, Guangzhou, CHN, 510627
Runben Biotechnology Co Ltd is engaged in research & development, production and sales of mosquito repellent and personal care products.
70GF Score

Get the complete analysis for SHSE:603193

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.54
Price
¥28.60
GF Value